1.
Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir
by Darcis, Gilles
AIDS (London), 2017-01-14, Vol.31 (2), p.181-189
2.
HIV-1 group P infection: towards a dead-end infection?
by Alessandri-Gradt, Elodie
AIDS (London), 2018-06-19, Vol.32 (10), p.1317-1322
3.
First evidence of transmission of an HIV-1 M/O intergroup recombinant virus
by Ngoupo, Paul Alain
AIDS (London), 2016-01-02, Vol.30 (1), p.1-8
4.
HIV-1 Pol Gene Polymorphism and Antiretroviral Resistance Mutations in Treatment-Naive Adult Patients in French Guiana Between 2006 and 2012
by Darcissac, Edith
AIDS research and human retroviruses, 2016-08, Vol.32 (8), p.801-811
5.
HIV-1 Genetic Diversity and Drug Resistance Mutations Among Treatment-Naive Adult Patients in Suriname
by Abdoel Wahid, Firoz
AIDS research and human retroviruses, 2016-12, Vol.32 (12), p.1223-1228
6.
Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1-infected HAART-treated patients
by BOUCHAT, Sophie
AIDS (London), 2012, Vol.26 (12), p.1473-1482
7.
Effect of selenium supplementation on CD4+ T-cell recovery, viral suppression and morbidity of HIV-infected patients in Rwanda: a randomized controlled trial
by Kamwesiga, Julius
AIDS (London), 2015-06-01, Vol.29 (9), p.1045-1052
8.
Defining total-body AIDS-virus burden with implications for curative strategies
by Estes, Jacob D
Nature medicine, 2017-11, Vol.23 (11), p.1271-1276
9.
Low Prevalence of Transmitted HIV Type 1 Drug Resistance Among Antiretroviral-Naive Adults in a Rural HIV Clinic in Kenya
by Hassan, Amin S.
AIDS research and human retroviruses, 2013-01-01, Vol.29 (1), p.129-135
10.
Defective proviruses rapidly accumulate during acute HIV-1 infection
by Bruner, Katherine M
Nature medicine, 2016-09, Vol.22 (9), p.1043-1049
11.
Gender differences in antiretroviral treatment outcomes of HIV patients in rural Uganda
by Kipp, Walter
AIDS care, 2010-03-01, Vol.22 (3), p.271-278
12.
Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less
by Bélec, Laurent
Future microbiology, 2011-11, Vol.6 (11), p.1251-1260
13.
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015 : the Global Burden of Disease Study 2015
by GBD 2015 HIV Collaborators
The Lancet (British edition), 2016-08, Vol.3 (8), p.361
14.
Rural Residence and Adoption of a Novel HIV Therapy in a National, Equal-Access Healthcare System
by Ohl, Michael
AIDS and behavior, 2011-12-29, Vol.17 (1), p.250-259
15.
The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption
by Li, Jonathan Z
AIDS (London), 2016-01-28, Vol.30 (3), p.343-353
16.
HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy
by Honeycutt, Jenna B
Nature medicine, 2017-05, Vol.23 (5), p.638-643
17.
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial
by McCormack, Sheena, Prof
The Lancet (British edition), 2016, Vol.387 (10013), p.53-60
18.
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals
by Bar-On, Yotam
Nature medicine, 2018-11, Vol.24 (11), p.1701-1707
19.
Broadly Neutralizing Antiviral Antibodies
by Corti, Davide
Annual review of immunology, 2013-03-21, Vol.31 (1), p.705-742
20.
Fc receptor but not complement binding is important in antibody protection against HIV
by Burton, Dennis R
Nature (London), 2007-09-06, Vol.449 (7158), p.101-104
